Principal Scientific Adviser chairs meeting to discuss Biomass Cultivation (See 'Corp Brief') SAFEMA - Appellant have furnished evidence which show satisfactorily that they took all reasonable steps to realise export proceeds : Tribunal (See 'Legal Desk') Companies Act - Winding up petition can be dismissed when contentions raised by parties constitute triable issues as Company Court cannot enter into adjudication of disputed facts of amount due and payable : HC (See 'Legal Desk') Competition Act - In absence of any apparent anti-competitive conduct, decision of purchase or sale of product and quantity thereof is driven by commercial considerations of market players : CCI (See 'Legal Desk') Slum Rehabilitation Act - Preferential right to owner is available only when someone other than owner is being preferred and owner has never before been given or availed of right to develop : HC (See 'Legal Desk') India Pavilion at World Hydrogen Summit showcases Green Hydrogen Mission (See 'Corp Brief') CPC - Application can be dismissed as Intervener has already initiated its own remedy by way of independent Execution Petition : HC (See 'Legal Desk') SEBI Act - Appellant has not shown sufficient cause for condonation of delay in filing appeal : SAT (See 'Legal Desk') PMLA - When questions relating to legality of arrest is under consideration, more holistic and libertarian view is to release Chief Minister of Delhi on interim bail for Lok Sabha General Elections : SC (See 'Legal Desk') Smugglers and Foreign Exchange Manipulators (Forfeiture of Property) Act, 1976 - Order for forfeiture of properties is rightly made as property is occupied through lllegal earning : Tribunal (See 'Legal Desk') Summer Power demand expected to be adequately met during both day and night (See 'Corp Brief') Arbitration Act - As petitioner is not notified as 'financial institution' or 'bank' under RDB Act, there is no bar on parallel proceedings to co-exist under A&C Act as well as SARFAESI Act : HC (See 'Legal Desk') Cr.P.C. - Once order issuing process has been set aside, then applicant has no right to file application u/s 482 of Cr.P.C. for quashment of complaint case : HC (See 'Legal Desk') Competition Act - WordPress.org is justified in taking appropriate action against any developer found non-compliant with prescribed standards and regulations : CCI (See 'Legal Desk') Ministry of Skill signs MoU with Mahindra Ltd to conduct two Pilot Projects (See 'Corp Brief')

Print

CSIR okays multi institutional project to develop human monoclonal antibodies

Published: May 09, 2020

By TIOLCORPLAWS News Service

NEW DELHI, MAY 09, CSIR is leading the fight against Covid-19 using multi-pronged approach and multiple models of engagement. On one hand CSIR labs themselves are developing technologies and products and are working with industry and PSU partners for deployment. On the other hand, CSIR is also supporting new ideas and projects from other academic and industries through its flagship New Millennium Indian Technology Leadership Initiative (NMITLI) program.

Given the importance of deploying multiple strategies against Covid-19, CSIR through NMITLI program has approved a project towards development of human monoclonal antibodies (hmAbs) that can neutralize SARS-CoV-2 in patients. This project on generation of neutralizing human monoclonal antibodies as a therapeutic strategy will be implemented by a multi-institutional and multi-disciplinary team. The team comprises of academic institutes and industry with participants from NCCS, IIT-Indore, PredOmix Technologies Pvt. Ltd. and Bharat Biotech International Ltd (BBIL)

The project aims to generate hmAbs to SARS-CoV-2 from convalescent phase of COVID-19 patients and select high affinity and neutralizing antibodies. The project also aims to anticipate future adaptation of the virus and generate hmAbs clones that can neutralize the mutated virus so that could be readily used for combating future SARS-CoV infections.BBIL will be the commercial partner and responsible for subsequent development and commercialization of the hmAbs generated.

DG CSIR, Dr Shekhar C Mande commented that “As the research into SARS-CoV-2 is in early days and our understanding is evolving each day, it is critical that we need to deploy all possible strategies to combat the virus. Hence, CSIR is exploring all avenues and we are supporting new ideas which have clear deployment strategy”.

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
tioltube
taxindiaonline
A Taxongo Website. Copyright © 2016-2022 tiolcorplaws.com All rights reserved.